MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.kint.2020.10.032

Медицинская библиотека · Kidney international · 2020

Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring.

Waldman Meryl, Soler Maria Jose, García-Carro Clara, Lightstone Liz, Turner-Stokes Tabitha, Griffith Megan, Torras Joan, Valenzuela Laura Martinez, Bestard Oriol, Geddes Colin, Flossmann Oliver, Budge Kelly L, Cantarelli Chiara, Fiaccadori Enrico, Delsante Marco, Morales Enrique, Gutierrez Eduardo, Niño-Cruz Jose A, Martinez-Rueda Armando J, Comai Giorgia, Bini Claudia, La Manna Gaetano, Slon Maria F, Manrique Joaquin, Agraz Irene, Sinaii Ninet, Cravedi Paolo

СтатьяПоддержка NIH: внешняя программаResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

The effects of SARS-CoV-2 infection on individuals with immune-mediated glomerulonephritis, who are often undergoing immunosuppressive treatments, are unknown. Therefore, we created the International Registry of COVID infection in glomerulonephritis (IRoc-GN) and identified 40 patients with glomerulonephritis and COVID-19 followed in centers in North America and Europe. Detailed information on glomerulonephritis diagnosis, kidney parameters, and baseline immunosuppression prior to infection were recorded, as well as clinical presentation, laboratory values, treatment, complications, and outcomes of COVID-19. This cohort was compared to 80 COVID-positive control cases from the general population without glomerulonephritis matched for the time of infection. The majority (70%) of the patients with glomerulonephritis and all the controls were hospitalized. Patients with glomerulonephritis had significantly higher mortality (15% vs. 5%, respectively) and acute kidney injury (39% vs. 14%) than controls, while the need for kidney replacement therapy was not statistically different between the two groups. Receiving immunosuppression or renin-angiotensin-aldosterone system inhibitors at presentation did not increase the risk of death or acute kidney injury in the glomerulonephritis cohort. In the cohort with glomerulonephritis, lower serum albumin at presentation and shorter duration of glomerular disease were associated with greater risk of acute kidney injury and need for kidney replacement therapy. No differences in outcomes occurred between patients with primary glomerulonephritis versus glomerulonephritis associated with a systemic autoimmune disease (lupus or vasculitis). Thus, due to the higher mortality and risk of acute kidney injury than in the general population without glomerulonephritis, patients with glomerulonephritis and COVID-19 should be carefully monitored, especially when they present with low serum albumin levels.

Для цитирования: Waldman Meryl, Soler Maria Jose, García-Carro Clara, Lightstone Liz, Turner-Stokes Tabitha, Griffith Megan, Torras Joan, Valenzuela Laura Martinez, Bestard Oriol, Geddes Colin, Flossmann Oliver, Budge Kelly L, Cantarelli Chiara, Fiaccadori Enrico, Delsante Marco, Morales Enrique, Gutierrez Eduardo, Niño-Cruz Jose A, Martinez-Rueda Armando J, Comai Giorgia, Bini Claudia, La Manna Gaetano, Slon Maria F, Manrique Joaquin, Agraz Irene, Sinaii Ninet, Cravedi Paolo. Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring.. Kidney international. 2020. DOI: 10.1016/j.kint.2020.10.032.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.